{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:33:16Z","timestamp":1782448396610,"version":"3.54.5"},"reference-count":48,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoid malignancies associated with poor prognosis due to ineffective treatment options and high rates of relapse. The success of chimeric antigen receptor T-cell (CART) therapy for certain hematologic malignancies makes it an attractive treatment option for PTCLs. However, shared expression of potential target antigens by both malignant and healthy T cells poses a challenge. Current prospective CART approaches cause a high degree of on-target, off-tumor activity, resulting in fratricide during CART expansion, depletion of healthy T\u00a0cells in\u00a0vivo, and immune compromise in the patient. To limit off-tumor targeting, we sought to develop a CART platform specific for a given T-cell receptor v\u03b2 (TCRv\u03b2) family that\u00a0would endow CAR-modified T cells with the ability to mediate lysis of the clonal malignant population while preserving the majority of healthy T cells. Here, CAR constructs specific for multiple TCRv\u03b2 family members were designed and validated. Our results demonstrate that TCRv\u03b2-family\u2013specific CARTs (TCRv\u03b2-CARTs) recognize and kill TCRv\u03b2-expressing target cells. This includes specific self-depletion of the targeted cell subpopulation in the CART product and lysis of cell lines engineered to express a target TCRv\u03b2 family. Furthermore, TCRv\u03b2-CARTs eliminated the dominant malignant TCRv\u03b2 clone\u00a0in 2 patient samples. Finally, in immunodeficient mice, TCRv\u03b2-CARTs eradicated malignant cells in a TCRv\u03b2-dependent manner. Importantly, the nontargeted TCRv\u03b2 families were spared in all cases. Thus, TCRv\u03b2-CART therapy provides a potential option for high-precision treatment of PTCL with limited healthy T-cell depletion.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008798","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T12:33:31Z","timestamp":1662122011000},"page":"1885-1898","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["TCRv\u03b2-CART therapy mediates high-precision targeting of malignant T-cell clones"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-2261","authenticated-orcid":false,"given":"Lauren C.","family":"Shaw","sequence":"first","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies and Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4603-3508","authenticated-orcid":false,"given":"Mathilde","family":"Poussin","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Rodriguez-Garcia","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4648-5114","authenticated-orcid":false,"given":"Joshua","family":"Eggold","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Minutolo","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies and Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2271-5886","authenticated-orcid":false,"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"4Division of Hematologic Malignancies and Cellular Therapies, Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[{"name":"5Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"6Division of Hematology Oncology, Lymphoma Program, Abramson Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-8908","authenticated-orcid":false,"suffix":"Jr","given":"Daniel J.","family":"Powell","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"25","key":"2023050516094388600_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023050516094388600_bib2","doi-asserted-by":"crossref","first-page":"djw248","DOI":"10.1093\/jnci\/djw248","article-title":"T-Cell lymphoma: recent advances in characterization and new opportunities for treatment","volume":"109","author":"Casulo","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"2023050516094388600_bib3","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023050516094388600_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"2023050516094388600_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nri2635","article-title":"Engineering lymphocyte subsets: tools, trials and tribulations","volume":"9","author":"June","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2023050516094388600_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"95","key":"2023050516094388600_bib7","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"16","key":"2023050516094388600_bib8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2023050516094388600_bib9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023050516094388600_bib10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023050516094388600_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"2023050516094388600_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A\u00a0phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"suppl 1","key":"2023050516094388600_bib13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2023050516094388600_bib14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T\u00a0cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"2023050516094388600_bib15","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"2023050516094388600_bib16","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.24794","article-title":"Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies","volume":"92","author":"Perera","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"2023050516094388600_bib17","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2023050516094388600_bib18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A\u00a0T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023050516094388600_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2023050516094388600_bib20","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u2018off-the-shelf\u2019 fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"68","key":"2023050516094388600_bib21","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"2023050516094388600_bib22","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"2023050516094388600_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front Oncol"},{"issue":"8","key":"2023050516094388600_bib24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/bioinformatics\/btw810","article-title":"Defining the clonality of peripheral T cell lymphomas using RNA-seq","volume":"33","author":"Brown","year":"2017","journal-title":"Bioinformatics"},{"issue":"1","key":"2023050516094388600_bib25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.iy.03.040185.002541","article-title":"Molecular genetics of the T cell-receptor beta chain","volume":"3","author":"Davis","year":"1985","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"2023050516094388600_bib26","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.4049\/jimmunol.146.12.4392","article-title":"The human T cell receptor beta-chain gene complex contains at least 57 variable gene segments. Identification of six V beta genes in four new gene families","volume":"146","author":"Robinson","year":"1991","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"2023050516094388600_bib27","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1073\/pnas.90.6.2433","article-title":"Organization of human T-cell receptor beta-chain genes: clusters of V beta genes are present on chromosomes 7 and 9","volume":"90","author":"Robinson","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"2023050516094388600_bib28","unstructured":"IMGT Repertoire (IG and TR)\n          . Immunogenetics database search engine. Deposited 17 October 1997. Available at:. Accessed 3 May 2022. https:\/\/imgt.org\/IMGTrepertoire\/."},{"issue":"3","key":"2023050516094388600_bib29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.0022-202X.2004.23586.x","article-title":"Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma","volume":"124","author":"Vonderheid","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"2023050516094388600_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0560.1996.tb01301.x","article-title":"T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skin","volume":"23","author":"Potoczna","year":"1996","journal-title":"J\u00a0Cutan Pathol"},{"issue":"12","key":"2023050516094388600_bib31","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"9","key":"2023050516094388600_bib32","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/QAD.0000000000002187","article-title":"Dimorphism in the T-cell receptor constant region affects T-cell function, phenotype and HIV outcome","volume":"33","author":"Kaewpreedee","year":"2019","journal-title":"AIDS"},{"issue":"9","key":"2023050516094388600_bib33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/s41375-019-0455-3","article-title":"Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies","volume":"33","author":"Huang","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"2023050516094388600_bib34","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.4049\/jimmunol.177.9.6548","article-title":"Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes","volume":"177","author":"Johnson","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"2023050516094388600_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1089\/hum.2014.006","article-title":"A\u00a0human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes","volume":"25","author":"Lanitis","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"2","key":"2023050516094388600_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nri1292","article-title":"The many important facets of T-cell repertoire diversity","volume":"4","author":"Nikolich-\u017dugich","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2023050516094388600_bib37","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"18","key":"2023050516094388600_bib38","first-page":"4408","article-title":"Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T cells and NK cells","volume":"10","author":"Salman","year":"2019","journal-title":"J\u00a0Cancer"},{"issue":"S1","key":"2023050516094388600_bib39","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1002\/ajh.25399","article-title":"Allogeneic CAR T cell therapies for leukemia","volume":"94","author":"Qasim","year":"2019","journal-title":"Am J Hematol"},{"issue":"35","key":"2023050516094388600_bib40","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"584","key":"2023050516094388600_bib41","doi-asserted-by":"crossref","first-page":"eabd3595","DOI":"10.1126\/scitranslmed.abd3595","article-title":"TCR \u03b2 chain\u2013directed bispecific antibodies for the treatment of T cell cancers","volume":"13","author":"Paul","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"2023050516094388600_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/leu.2014.261","article-title":"Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis","volume":"29","author":"Schatz","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2023050516094388600_bib43","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2017.241","article-title":"CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype","volume":"29","author":"Li","year":"2018","journal-title":"Hum Gene Ther"},{"key":"2023050516094388600_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin\u2019s Lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol Ther Oncolytics"},{"issue":"440","key":"2023050516094388600_bib45","doi-asserted-by":"crossref","first-page":"eaar5894","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-throughput sequencing of the T cell receptor \u03b2 gene identifies aggressive early-stage mycosis fungoides","volume":"10","author":"de Masson","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023050516094388600_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fonc.2019.00176","article-title":"The emergence of universal immune receptor T cell therapy for cancer","volume":"9","author":"Minutolo","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"2023050516094388600_bib47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/vaccines8040631","article-title":"A\u00a0novel approach for the treatment of T cell malignancies: targeting T cell receptor V\u03b2 families","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines"},{"issue":"18","key":"2023050516094388600_bib48","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1885\/2049104\/blooda_adv-2022-008798-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1885\/2049104\/blooda_adv-2022-008798-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T12:10:17Z","timestamp":1683288617000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/9\/1885\/486494\/TCRv-CART-therapy-mediates-high-precision"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008798","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742306486.793596126","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]}}}